OCGN vs. TRML, SLDB, TCRX, REPL, BDTX, ALVO, AURA, FATE, LXEO, and ITOS
Should you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include Tourmaline Bio (TRML), Solid Biosciences (SLDB), TScan Therapeutics (TCRX), Replimune Group (REPL), Black Diamond Therapeutics (BDTX), Alvotech (ALVO), Aura Biosciences (AURA), Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), and iTeos Therapeutics (ITOS). These companies are all part of the "biological products, except diagnostic" industry.
Tourmaline Bio (NASDAQ:TRML) and Ocugen (NASDAQ:OCGN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, community ranking, valuation, earnings, dividends, analyst recommendations and risk.
Ocugen's return on equity of -19.56% beat Tourmaline Bio's return on equity.
Ocugen received 92 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 68.92% of users gave Ocugen an outperform vote.
In the previous week, Ocugen had 1 more articles in the media than Tourmaline Bio. MarketBeat recorded 24 mentions for Ocugen and 23 mentions for Tourmaline Bio. Ocugen's average media sentiment score of 0.51 beat Tourmaline Bio's score of 0.44 indicating that Tourmaline Bio is being referred to more favorably in the media.
91.9% of Tourmaline Bio shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 11.0% of Tourmaline Bio shares are held by insiders. Comparatively, 3.5% of Ocugen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Tourmaline Bio has higher earnings, but lower revenue than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than Tourmaline Bio, indicating that it is currently the more affordable of the two stocks.
Tourmaline Bio has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 3.49, meaning that its share price is 249% more volatile than the S&P 500.
Tourmaline Bio presently has a consensus target price of $61.80, indicating a potential upside of 310.90%. Ocugen has a consensus target price of $4.67, indicating a potential upside of 144.33%. Given Ocugen's higher possible upside, research analysts clearly believe Tourmaline Bio is more favorable than Ocugen.
Summary
Tourmaline Bio beats Ocugen on 10 of the 15 factors compared between the two stocks.
Get Ocugen News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
